The VICI-DISEASE Consortium

The VICI-DISEASE consortium’s main objective is to exploit a phase-III validated capsid Virus Like Particle (cVLP) vaccine platform to develop a vaccine candidate portfolio and perform a clinical proof-of-concept study, to enable stocks of vaccine candidates ready for further development (Phase 2&3) in case of pandemic outbreaks.

The primary candidate will be Nipah virus (NiV), a high-mortality viral disease with no vaccines or treatments. We address the call topic by improving pandemic preparedness and response through development of a NiV vaccine to Ph1/2 and two filovirus vaccines to pre-clinical proof-of-concept.

VICI-Disease

     

    Project title: Protection from viruses with epidemic and pandemic disease outbreak potential through development and clinical testing of a novel capsid virus like particle (CVLP) vaccine. 

    Acronym: VICI-DISEASE

    Aim: To develop a Nipah virus (NiV) vaccine candidate based on a capsid virus-like particle platform.

    Period: 01-12-2023  to 30-11-2027

    Partners: University of Copenhagen, AdaptVac,
    STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (RADBOUDUMC), FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT (FLI), EXPRES2ION BIOTECHNOLOGIES,  UNIVERSITAET LEIPZIG (ULEI).

    Funder: the European Union

    Total grant: 8 million Euro

     

     

    TBA ...